Procept BioRobotics Corporation (PRCT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX 
PROCEPT BioRobotics Corporation (PRCT) Q2 2025 Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Kevin Waters - Executive VP & CFO Larry L. Wood - Independent Director Matthew James Bacso - Vice President of Investor Relations Reza Zadno - President, CEO & Director Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C.
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Lags Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.5 per share a year ago.
Will PROCEPT BioRobotics Corporation (PRCT) Report Negative Earnings Next Week? What You Should Know
PROCEPT BioRobotics (PRCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PROCEPT BioRobotics Corporation (PRCT) Q1 2025 Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations & Business Operations Reza Zadno - President & Chief Executive Officer Sham Shiblaq - Executive Vice President & Chief Commercial Officer Kevin Waters - Executive Vice President & Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Craig Bijou - Bank of America Securities Patrick Wood - Morgan Stanley Richard Newitter - Truist Brandon Vazquez - William Blair Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Mike Kratky - Leerink Partners Nathan Treybeck - Wells Fargo Michael Sarcone - Jefferies Ryan Zimmerman - BTIG Operator Good morning and welcome to PROCEPT BioRobotics First Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode.
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.51 per share a year ago.
Procept BioRobotics: Strong Growth, But Profitability Seems Far Away
PROCEPT BioRobotics shows strong revenue growth and expanding market presence but struggles with profitability and rising operational costs. The company's HYDROS robotic system and consumables business are driving revenue, with significant expansion in the U.S. and promising international growth. The FDA's clearance for Aquablation therapy in prostate cancer patients presents a long-term opportunity, though profitability remains a distant goal.
PROCEPT BioRobotics Corporation (PRCT) Q4 2024 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Q4 2024 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.54 per share a year ago.
PROCEPT BioRobotics (PRCT) Upgraded to Strong Buy: Here's What You Should Know
PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Procept BioRobotics resumed with an Overweight at Wells Fargo
Wells Fargo resumed coverage of Procept BioRobotics with an Overweight rating and $112 price target. The firm believes aquablation remains early stages in its adoption, which will be further supported by a new product cycle, the analyst tells investors in a research note. Procept is comfortable with 2025 consensus estimates, Wells says, adding that the firm is receiving "generally positive" physician feedback on Hydros.
Procept BioRobotics: Continued Growth Runway Ahead
PRCT's Q3 sales were up 66% YoY, and gross margins reached a record 63%. Management forecasts $223mm in sales this year, with a 64% top-line growth. The business model ensures recurring revenue and operating leverage.
Are You Looking for a Top Momentum Pick? Why PROCEPT BioRobotics Corporation (PRCT) is a Great Choice
Does PROCEPT BioRobotics Corporation (PRCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
